- Home
- ACXP vs CRIS Comparison
ACXP vs CRIS Comparison
Compare ACXP & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- CRIS
- Stock Information
- Founded
- ACXP 2017
- CRIS 2000
- Country
- ACXP United States
- CRIS United States
- Employees
- ACXP N/A
- CRIS N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACXP Health Care
- CRIS Health Care
- Exchange
- ACXP Nasdaq
- CRIS Nasdaq
- Market Cap
- ACXP 31.4M
- CRIS 31.2M
- IPO Year
- ACXP 2021
- CRIS 2000
- Fundamental
- Price
- ACXP $1.77
- CRIS $4.00
- Analyst Decision
- ACXP Strong Buy
- CRIS Strong Buy
- Analyst Count
- ACXP 1
- CRIS 3
- Target Price
- ACXP $12.00
- CRIS $23.00
- AVG Volume (30 Days)
- ACXP 35.4K
- CRIS 68.2K
- Earning Date
- ACXP 11-12-2024
- CRIS 11-14-2024
- Dividend Yield
- ACXP N/A
- CRIS N/A
- EPS Growth
- ACXP N/A
- CRIS N/A
- EPS
- ACXP N/A
- CRIS N/A
- Revenue
- ACXP N/A
- CRIS $10,161,000.00
- Revenue This Year
- ACXP N/A
- CRIS N/A
- Revenue Next Year
- ACXP N/A
- CRIS N/A
- P/E Ratio
- ACXP N/A
- CRIS N/A
- Revenue Growth
- ACXP N/A
- CRIS N/A
- 52 Week Low
- ACXP $1.52
- CRIS $3.70
- 52 Week High
- ACXP $5.28
- CRIS $17.49
- Technical
- Relative Strength Index (RSI)
- ACXP 31.97
- CRIS 32.54
- Support Level
- ACXP $1.82
- CRIS $3.70
- Resistance Level
- ACXP $1.89
- CRIS $4.55
- Average True Range (ATR)
- ACXP 0.08
- CRIS 0.42
- MACD
- ACXP -0.00
- CRIS -0.04
- Stochastic Oscillator
- ACXP 17.39
- CRIS 23.70
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.